The 2024 Clinical Trials Transformation Initiative (CTTI) report, drawing on a broad spectrum of responses from diverse stakeholders in the clinical trial community, sheds light on the significant challenges faced and the pressing need for improved reporting guidance and training from the FDA. With contributors ranging from academia to industry, the report reflects a universal concern across the clinical research sector, emphasizing the vital role of clear communication and robust support systems in maintaining the integrity of clinical trials.

What Happens if Researchers Don’t Adhere to Reporting Guidelines?

The FDA’s guidelines for clinical trial registration and reporting on are in place to ensure transparency in clinical research – and the FDA enforces these requirements by law. Non-compliance can lead to significant ramifications, including legal consequences (i.e., civil monetary penalties and, in certain cases, other legal actions may be pursued), publishing results challenges, and future funding implications. Despite this enforcement, many researchers exhibit challenges with reporting on

Unpacking the Reporting Conundrum

The CTTI report highlights substantial challenges in registering clinical trials and reporting summary results on Primary hurdles include understanding the complex registration requirements, dealing with the absence of well-specified outcomes in protocols, and difficulties in harmonizing standards with other regulatory agencies, leading to confusion and inconsistency. Reporting challenges stem from the nuances of regulatory timelines, apprehensions about premature disclosure of results, especially before academic publication, and the daunting task of ensuring the accuracy and completeness of reported data. These complexities make comprehensive compliance challenging for researchers, indicating a need for clearer guidance and resources from the FDA.

The Data Unveils These Challenges

Survey participants express a unified struggle, from regulatory affairs supervisors and specialists to scientific and clinical operations staff. Specifically, the responsible party’s understanding of reporting requirements and a lack of well-specified outcomes in protocols have been reported as challenges by 52.2% and 51.1% of respondents, respectively (Figure 1). Additionally, there were challenges with reporting clinical trial results, as 56.5% of respondents exhibited concerns about reporting before publication and understanding results submissions (Figure 2).

Figure 1: Challenges Related to Registering on
Figure 1 Challenges Related to Registering Clinical Trials
Figure 2 Challenges for Reporting of Summary Results Information

A Rallying Cry for FDA Resources for

In the survey, stakeholders have expressed a clear need for additional educational and compliance resources. According to the CTTI report, there is a significant demand for more comprehensive training materials and guidance. A notable 77.2% of respondents called for tutorials and tip sheets that keep pace with evolving regulations, while 69.6% see the benefit of having a list of common mistakes available during the Protocol Registration and Results System (PRS) review process (Figure 3).

Similarly, the call for resources on compliance is equally pressing. The data shows that 62.0% of respondents seek pre-recorded informational sessions on compliance, indicating a preference for accessible and self-paced learning tools. Additionally, the demand for better communication around FDA guidances, requested by 56.5%, highlights the need for clearer and more direct guidelines from regulatory bodies (Figure 4).

These findings underline the critical role of effective educational tools and clear communication in enhancing clinical trial transparency and compliance, serving as a roadmap for future improvements in reporting.

Figure 3 Suggested Educational Resources
Figure 4 Suggested Resources on Compliance

The FDA Needs to Take Action to Help Researchers

While resources exist, the CTTI survey responses indicate a need for more resources. While the data does not explicitly confirm noncompliance, it indicates a heightened risk of it occurring due to these systemic shortcomings and points to an underlying issue in the clinical trial reporting system. This challenge appears to be less about the willingness of researchers to comply and more about the insufficiency of resources and clear guidance provided by the FDA. The FDA must take action by enhancing the support and clarity of reporting, which could significantly reduce the likelihood of noncompliance and improve clinical trials’ overall efficacy and transparency.

What We Might See From FDA:

Based on how the FDA has responded to researchers’ needs, we might expect the FDA to assist by:

  • Developing a Comprehensive Guidance Document: The FDA might create a detailed guidance document that outlines the registration and reporting requirements, and addresses reported challenges, for example, distinguishing between different types of trials that need registration and timelines for reporting results.
  • Offering Recorded Training Sessions: The FDA may conduct training sessions or webinars that delve into the practical aspects of reporting processes. These could highlight common pitfalls, like issues reporting outcomes for unsuccessful trials or managing data confidentiality, and offer step-by-step solutions.
  • Establishing a Support Center for Personalized Assistance: While a bit farfetched, the FDA may set up a dedicated helpdesk to provide real-time support, which could be very helpful to researchers. This center might be capable of guiding researchers through complex scenarios, such as navigating changes in trial status or updating trial outcomes in line with evolving FDA and international guidelines.


The findings of the CTTI report serve as a stark reminder of the gaps in the reporting process and highlight the necessity of immediate action from the FDA to step up in providing clearer guidelines and accessible educational materials but also stress the importance of such measures in upholding the transparency and reliability of clinical research. As the medical research community advances, the regulatory frameworks and support systems must evolve concurrently, ensuring that clinical trials are reported with integrity and openness.

author avatar
Moe Alsumidaie Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.